These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 8808830)

  • 1. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
    Kobayashi H; Gotoh J; Hirashima Y; Fujie M; Sugino D; Terao T
    J Biol Chem; 1995 Apr; 270(14):8361-6. PubMed ID: 7713945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
    Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
    Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
    Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
    Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase induces receptor mediated brain tumor cell migration and invasion.
    MacDonald TJ; DeClerck YA; Laug WE
    J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models.
    Kobayashi H; Shinohara H; Fujie M; Gotoh J; Itoh M; Takeuchi K; Terao T
    Int J Cancer; 1995 Nov; 63(3):455-62. PubMed ID: 7591248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis.
    Kobayashi H; Shinohara H; Takeuchi K; Itoh M; Fujie M; Saitoh M; Terao T
    Cancer Res; 1994 Feb; 54(3):844-9. PubMed ID: 8306348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.
    Kobayashi H; Gotoh J; Kanayama N; Hirashima Y; Terao T; Sugino D
    Cancer Res; 1995 May; 55(9):1847-52. PubMed ID: 7728751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
    Stahl A; Mueller BM
    Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
    Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
    Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.